Biotech News

Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London

Intellia (NTLA)IntelliaConference / presentation

CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will present at the Jefferies Global

Related news

Intellia

In Vivo CRISPR Gene Editing Intellia Therapeutics develops potentially one-time medicines using CRISPR-based gene editing. Its lead programs edit disease-causing genes directly inside the body through systemically delivered therapies. Hereditary Angioedema Lonvoguran ziclumeran, or lonvo-z, is an in vivo gene-editing candidate designed...

Recent company news

Stock data

Close
9.52 USD
Market cap
1.83B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States